Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
As Bayer confronts mounting Roundup losses, all eyes on Philadelphia trial
06:09am, Monday, 04'th Dec 2023
With Bayer facing investor pressure to resolve thousands of lawsuits over its Roundup weedkiller after being hit with $2 billion in verdicts in recent weeks, all eyes are on a trial wrapping up in Phi
3 Battered Blue-Chip Stocks to Sell in December
06:30am, Tuesday, 28'th Nov 2023
The market continues to rip higher in November, with the S&P 500 up 9% since Halloween. However, not all stocks are participating in the rally.
Exclusive: Bayer holds call with bond investors after raft of bad news
05:41pm, Wednesday, 22'nd Nov 2023
Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects ahead of a $5.75 billion bond issuance, t
Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy
01:32pm, Monday, 20'th Nov 2023
Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.
Cramer's Mad Dash: Bayer AG
10:41am, Monday, 20'th Nov 2023
CNBC's Jim Cramer delivers his daily Mad Dash.
Bayer shares plunge to a near two-decade low after blood thinner trial failure
09:11am, Monday, 20'th Nov 2023
Bayer AG (ETR:BAYN, OTC:BAYZF), the German pharmaceutical giant, has seen its shares tank more than 20% to a near 18-year low following the failure of a key drug trial and legal challenges in the Un
Bayer shares plunge by more than 20% after trial of potential blockbuster drug halted
06:33am, Monday, 20'th Nov 2023
Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug asundexian due to a
Bayer Stock Drops to Lowest Since 2009 as Blood Thinner Trial Fails
05:49am, Monday, 20'th Nov 2023
Bayer says late-stage testing of a drug called asundexian used to treat heart disease would be stopped because it didn't appear to be effective.
Bayer cancels asundexian phase III study program
07:18pm, Sunday, 19'th Nov 2023
Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller
11:35am, Sunday, 19'th Nov 2023
A Missouri jury ordered Bayer to pay $1.56 billion to four plaintiffs who claimed the company's Roundup weedkiller caused injuries including cancer, a verdict that could intensify investor pressure on
Bayer Told to Pay $1.56 Billion After Losing Roundup Case
07:43pm, Saturday, 18'th Nov 2023
A Missouri jury found in favor of plaintiffs as verdicts seesaw in trials involving the fertilizer.
Bayer recalls one lot of cancer drug Vitrakvi
05:52pm, Friday, 17'th Nov 2023
Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi due to the presence of microbial contamination.
Bayer withdraws follicular lymphoma drug after further trial fails
10:32am, Monday, 13'th Nov 2023
Bayer on Monday said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market after a trial designed to confirm its benefit did not show the d
European regulator endorses high-dose version of Bayer eye drug Eylea
09:10am, Friday, 10'th Nov 2023
Bayer said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the elderly, stepping up com
Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates
01:31pm, Wednesday, 08'th Nov 2023
Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.
